Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 18/20 | 0.68 |
| ▸ | CCND1 | P24385 | 17/20 | 0.68 |
| ▸ | CDK2 | P24941 | 15/20 | 0.68 |
| ▸ | CCNE2 | O96020 | 14/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090159 | 0.87 | CDK4 (0.71) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7146443 | 0.85 | CDK4 (0.68) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7145484 | 0.85 | CDK4 (0.68) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7148608 | 0.83 | CDK4 (0.66) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7091188 | 0.77 | CCNE2 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7140772 | 0.75 | CDK4 (0.70) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL12856433 | 0.74 | CDK2 (0.55) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7093050 | 0.74 | CCNE1 (0.55) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL20035506 | 0.73 | ALDH1A1 (0.53) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7147568 | 0.72 | CDK4 (0.67) | CDK4CCND1CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CDK4 195/4885CCND1 1476/4885CDK2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.